Upgrade to SI Premium - Free Trial

BMO Capital on SAGE Therapeutics (SAGE): 'Another Important Milestone Achieved with Brexanolone Filing for PPD'

April 23, 2018 10:23 AM
BMO Capital maintains Outperform on Sage Therapeutics (NASDAQ: SAGE) price target of $203.00.Analyst Gary Nachman comments "SAGE announced the NDA ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles